@article{bc85bece73424ccaa39b4c08f2c72260,
title = "Intermittent versus continuous first-line treatment for HER2-negative metastatic breast cancer: the Stop & Go study of the Dutch Breast Cancer Research Group (BOOG)",
keywords = "Metastatic breast cancer, Chemotherapy, Scheduling, Duration, Paclitaxel, Bevacizumab, BEVACIZUMAB PLUS PACLITAXEL, PHASE-III TRIAL, LOCALLY RECURRENT, OPEN-LABEL, DOUBLE-BLIND, CHEMOTHERAPY, THERAPY, CAPECITABINE, SURVIVAL, EFFICACY",
author = "Claessens, {Anouk K. M.} and Bos, {Monique E. M. M.} and Marta Lopez-Yurda and Bouma, {Jeanette M.} and Rademaker-Lakhai, {Jeany M.} and Honkoop, {Aafke H.} and {de Graaf}, Hiltje and {van Druten}, Edith and {van Warmerdam}, {Laurence J. C.} and {van der Sangen}, {Maurice J. C.} and Tjan-Heijnen, {Vivianne C. G.} and Erdkamp, {Frans L. G.} and {Dutch Breast Canc Res Grp BOOG}",
year = "2018",
month = nov,
day = "1",
doi = "10.1007/s10549-018-4906-8",
language = "English",
volume = "172",
pages = "413--423",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer, Cham",
number = "2",
}